A team of American researchers could avoid the accumulation of the brain of toxic proteins that cause Alzheimer's. Tests have been done so far in laboratory mice, but soon they could be tried on people, according to RTE. The new vaccine contains a DNA-coding segment of the beta-amyloid protective block. In the investigation, the vaccine triggered an immune response, which not only led to a 40% reduction in beta-amyloid formation, but also reduced your protein by 50%. The research was carried out on mice genetically made to develop a casting equivalent of Alzheimer's disease, says adevarul.ro.
"This study is the result of a decade of research that has often shown that this vaccine can reliably identify and reliably identify animals that we think can cause Alzheimer's disease," said Dr. Roger Rosenberg, director of the team of Research, director of the Center for Alzheimer's, University of Texas, cited by agerpres.ro. "I think we're getting closer to trying this therapy for people," he said. An important obstacle to the development of effective anti-Alzheimer vaccines was to look for ways to introduce them into the body.
A previous experimental vaccine, developed in the early 2000s, caused some brain tumors in some patients when people were tried. The new vaccine is injected in the skin instead of the muscle, which leads to another type of immune response. If the effects observed in mice repeat in humans, this vaccine would have "greater therapeutic value," said the researchers. "If the beginning of the disease could be delayed for five years, it would be huge for patients and their families," study co-author Doris Lambracht Washington, another member of the Texas University team. "The number of dementia cases could fall by half," he said. Some drugs target cerebral amylid protein stores and you are developing or clinically tested. But an effective vaccine would be a better strategy, according to researchers at the University of Texas. It would be more accessible and less expensive. At the beginning of this year, the same team of researchers found the exact point where a molecule became harmful but not yet formed "masses" in the brain.
The scientists also work on a spine fluid test that can detect your abnormal protein before the symptoms of the disease appear. Such a test could identify people who have no symptoms, but have high tau and amyloid levels in the brain. Patients identified by this test may be candidates for treatment with the vaccine. "The more you wait, the less it will have. After these boards and branches have formed, it may be too late," explained Dr. Rosenberg. The results of the research were published in Alzheimer's Research And Therapy. Up to now it is known that two types of toxic proteins play a key role in the development of Alzheimer-beta-amyloid disease and yours. Beta-amyloid and your brain accumulate in the brain and cause the destruction of nerve cells. Some research suggests that the two are linked, beta-amiloides, which favor the formation of "agglomerates" caused by your protein.